Key statistics
On Friday, MeiraGTx Holdings PLC (328:MUN) closed at 6.20, -21.02% below its 52-week high of 7.85, set on Oct 29, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 6.20 |
|---|---|
| High | 6.20 |
| Low | 6.20 |
| Bid | 6.20 |
| Offer | 6.40 |
| Previous close | 6.65 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 80.49m |
| Free float | 54.13m |
| P/E (TTM) | -- |
| Market cap | 579.53m USD |
| EPS (TTM) | -2.11 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 07:06 GMT.
More ▼
- MeiraGTx Reports Third Quarter 2025 Financial and Operational Results
- MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology
- MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
- MeiraGTx Reports Second Quarter 2025 Financial and Operational Results
- MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
- MeiraGTx Reports First Quarter 2025 Financial and Operational Results
- MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
- MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates
- MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process
- MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy
More ▼
